SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a double downgrade from Raymond James, driven by the U.S. Space Force's decision to recompete the $1.4B SCAR program, AeroVironment's largest contract. This news sparked a sharp sell-off, igniting community debate over whether the market is overreacting or legitimately repricing future revenue visibility.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is trending as escalating Middle East tensions drive up oil prices, with the community actively discussing its substantial price action and anticipating a significant short squeeze due to high borrow rates and minimal shares available to short.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East tensions, including drone strikes on oil facilities and LNG production halts, ignite strong community debate about surging energy prices and the stock's potential for a significant speculative run, though some warn of manipulation and dilution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Speculation is rampant around POET Technologies as NVIDIA's increasing focus on optical interconnects for AI data centers and Marvell's acquisition of Celestial AI validate the photonics sector, with the community anticipating significant partnership announcements and a revenue ramp, potentially coinciding with the upcoming OFC conference.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a central topic of discussion amid rising geopolitical tensions and the US Army's "Drone Dominance Program," with the community actively speculating on unprecedented demand for its drone and robotic solutions. Recent institutional boosts and public endorsements from military figures are fueling excitement for potential significant government contracts.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

The recent regulatory setback for a key competitor's Cushing's drug is driving significant attention to Xeris Biopharma, further fueled by robust financial performance and the advancement of a major pipeline candidate into Phase 3. While the company demonstrates strong fundamentals and growth potential, community discussions reflect ongoing frustration with the stock's pronounced volatility despite these positive developments.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as strategic partnerships with NVIDIA and Amazon AWS solidify its role in building next-generation AI-ready 5G and 6G network infrastructure. The community is buzzing with optimism, eyeing a potential breakout and recognizing the company's transformation as a key enabler of the AI supercycle.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending amid a strong earnings report and a new LNG supply agreement, with the community highly focused on how escalating geopolitical tensions in the Middle East, including disruptions to Qatar's LNG production, amplify the immediate demand for its rapidly expanding export capacity.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is seeing intense debate and volatility as its PDUFA date approaches for reproxalap, with community members clashing over the significance of recent financial disclosures, the CEO's conference remarks, a key executive's departure, and the FDA's silence on a critical labeling communication deadline, fueling both strong approval hopes and fears of a third Complete Response Letter.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics (NTLA) is seeing significant investor attention and a surge in price after the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial. This development, coupled with high short interest, is fueling strong short squeeze sentiment and optimism among the community that the stock will return to prior levels, especially given discussions around the patient death being unrelated to the therapy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury.</li><li>Prior Phase 2a results had already shown favorable safety and tolerability, as well as reduced disease progression.</li><li>Stocktwits users speculated that short selling could be the reason behind the stock’s decline.</li></ul>GRI Bio, Inc. (GRI), on Wednesday, announced encouraging new results from its Phase 2a study of GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF), a chronic and progressive lung disease.The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar repair compared with placebo.<h2 class="st-heading-2">Treatment May Support Lung Tissue Regeneration</h2>Crucially, the new data indicate that GRI-0621 may support the regeneration of lung tissue, including the repair of the alveolar basement membrane and the&nbsp;transition of AT2 (Alveolar Type) epithelial cells to AT1, which are key steps in restoring lung function.Prior Phase 2a results had already shown favorable safety and tolerability, reduced disease progression, and improvements in exploratory endpoints, such as forced vital capacity, with twice as many treated patients maintaining lung function compared with standard care.“The data from the Phase 2a study exceed our expectations. The totality of data generated in this Phase 2a study suggests that GRI-0621 may represent a fundamentally different approach, with the potential to alter the trajectory of disease by promoting repair of damaged lung tissue,” said Marc Hertz, chief executive officer of GRI Bio.<h2 class="st-heading-2">Short Selling Speculation</h2>However, despite the seemingly positive development, <a href="https://stocktwits.com/symbol/GRI">GRI shares</a> fell 20%. But users remained bullish, despite what many speculated as short selling.<stembedurl>https://stocktwits.com/Tradebub/message/643136568</stembedurl><stembedurl>https://stocktwits.com/Kookoovia/message/643141732</stembedurl>Despite the sharp intra-day decline, retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier. GRI was also among the top trending tickers on the platform.<h2 class="st-heading-2">Reverse Split</h2>Last week, GRI Bio announced a 1-for-28 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.The action became effective after-market hours on January 23, 2026, while trading on an ex-reverse split basis began on Monday. The split reduced outstanding shares from about 15 million to 536,000.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sbux-stock-climbs-7-premarket-after-q1-results/cmyg421R40I">SBUX Stock Jumps 7% Today – US Transactions Grow For The First Time In Two Years</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened?

The company said that the new data indicate that GRI-0621 may support the regeneration of lung tissue.

Equity

GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs

GRI Bio shared promising data from a Phase 2a trial for idiopathic pulmonary fibrosis, a chronic lung disease with no known cause.read more...

Barclays lifts Kojamo, I-RES ratings; cuts Grainger on low yield

This account has been verified as an official GRI representative.

Verified Account

GRI Bio

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

GRI
GRI Bio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest GRI News

GRIGRI Bio Inc